BACKGROUND: Highly lethal outbreaks of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are increasing. Whole-genome sequencing of KwaZulu-Natal MDR and XDR outbreak strains prevalent in human immunodeficiency virus (HIV)-infected patients by the Broad Institute identified 22 novel mutations which were unique to the XDR genome or shared only by the MDR and XDR genomes and not already known to be associated with drug resistance. METHODS: We studied the 12 novel mutations which were not located in highly-repetitive genes to identify mutations that were truly associated with drug resistance or were likely to confer a specific fitness advantage. RESULTS: None of these mutations could be found in a phylogenetically and geographically diverse set of drug-resistant and drug-susceptible Mycobacterium tuberculosis isolates, suggesting that these mutations are unique to the KZN clone. Examination of the 600-basepair region flanking each mutation revealed 26 new mutations. We searched for a convergent evolutionary signal in the new mutations for evidence that they emerged under selective pressure, consistent with increased fitness. However, all but 1 rare mutation were monophyletic, indicating that the mutations were markers of strain phylogeny rather than fitness or drug resistance. CONCLUSIONS: Our results suggest that virulent XDR tuberculosis in immunocompromised HIV-infected patients can evolve without generalizable fitness changes or other XDR-specific mutations.
BACKGROUND: Highly lethal outbreaks of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are increasing. Whole-genome sequencing of KwaZulu-Natal MDR and XDR outbreak strains prevalent in human immunodeficiency virus (HIV)-infectedpatients by the Broad Institute identified 22 novel mutations which were unique to the XDR genome or shared only by the MDR and XDR genomes and not already known to be associated with drug resistance. METHODS: We studied the 12 novel mutations which were not located in highly-repetitive genes to identify mutations that were truly associated with drug resistance or were likely to confer a specific fitness advantage. RESULTS: None of these mutations could be found in a phylogenetically and geographically diverse set of drug-resistant and drug-susceptible Mycobacterium tuberculosis isolates, suggesting that these mutations are unique to the KZN clone. Examination of the 600-basepair region flanking each mutation revealed 26 new mutations. We searched for a convergent evolutionary signal in the new mutations for evidence that they emerged under selective pressure, consistent with increased fitness. However, all but 1 rare mutation were monophyletic, indicating that the mutations were markers of strain phylogeny rather than fitness or drug resistance. CONCLUSIONS: Our results suggest that virulent XDR tuberculosis in immunocompromised HIV-infectedpatients can evolve without generalizable fitness changes or other XDR-specific mutations.
Authors: Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191
Authors: Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan Journal: Science Date: 2006-06-30 Impact factor: 47.728
Authors: Manzour Hernando Hazbón; Miriam Bobadilla del Valle; Marta Inírida Guerrero; Mandira Varma-Basil; Ingrid Filliol; Magali Cavatore; Roberto Colangeli; Hassan Safi; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Amy Davidow; Michael Brimacombe; Clara Inés León; Tania Porras; Mridula Bose; Fernando Chaves; Kathleen D Eisenach; José Sifuentes-Osornio; Alfredo Ponce de León; M Donald Cave; David Alland Journal: Antimicrob Agents Chemother Date: 2005-09 Impact factor: 5.191
Authors: Ingrid Filliol; Alifiya S Motiwala; Magali Cavatore; Weihong Qi; Manzour Hernando Hazbón; Miriam Bobadilla del Valle; Janet Fyfe; Lourdes García-García; Nalin Rastogi; Christophe Sola; Thierry Zozio; Marta Inírida Guerrero; Clara Inés León; Jonathan Crabtree; Sam Angiuoli; Kathleen D Eisenach; Riza Durmaz; Moses L Joloba; Adrian Rendón; José Sifuentes-Osornio; Alfredo Ponce de León; M Donald Cave; Robert Fleischmann; Thomas S Whittam; David Alland Journal: J Bacteriol Date: 2006-01 Impact factor: 3.490
Authors: Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: David Alland; David W Lacher; Manzour Hernando Hazbón; Alifiya S Motiwala; Weihong Qi; Robert D Fleischmann; Thomas S Whittam Journal: J Clin Microbiol Date: 2006-11-01 Impact factor: 5.948
Authors: Elena N Ilina; Egor A Shitikov; Larisa N Ikryannikova; Dmitry G Alekseev; Dmitri E Kamashev; Maja V Malakhova; Tatjana V Parfenova; Maxim V Afanas'ev; Dmitry S Ischenko; Nikolai A Bazaleev; Tatjana G Smirnova; Elena E Larionova; Larisa N Chernousova; Alexey V Beletsky; Andrei V Mardanov; Nikolai V Ravin; Konstantin G Skryabin; Vadim M Govorun Journal: PLoS One Date: 2013-02-20 Impact factor: 3.240
Authors: Sandhya Shekar; Zhen Xuan Yeo; Joshua C L Wong; Maurice K L Chan; Danny C T Ong; Pumipat Tongyoo; Sin-Yew Wong; Ann S G Lee Journal: PLoS One Date: 2014-07-15 Impact factor: 3.240
Authors: Kristen L Jurcic Smith; Divey Saini; Svetoslav Bardarov; Michelle Larsen; Richard Frothingham; Neel R Gandhi; William R Jacobs; A Willem Sturm; Sunhee Lee Journal: PLoS One Date: 2014-04-14 Impact factor: 3.240